Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy

Despite the overall clinical success of immune checkpoint inhibitors (ICIs) for treating patients with solid tumors, a large number of patients do not benefit from this approach. Consequently, there is a need for predictive biomarkers. The most prevalent biomarkers such as PD-L1 expression and tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Christina, Nissen, Neel I., Von Arenstorff, Claus S., Karsdal, Morten A., Willumsen, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520279/
https://www.ncbi.nlm.nih.gov/pubmed/34656158
http://dx.doi.org/10.1186/s13046-021-02133-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520279/
https://www.ncbi.nlm.nih.gov/pubmed/34656158
http://dx.doi.org/10.1186/s13046-021-02133-z

Ejemplares similares